Drug Profile
EPI N06
Alternative Names: EPI-N06Latest Information Update: 29 Aug 2019
Price :
$50
*
At a glance
- Originator EpiPharm AG
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Malignant melanoma; Nevus
Most Recent Events
- 29 Aug 2019 Phase-I/II development is ongoing in Switzerland (EpiPharm AG, August 2019)
- 07 Jan 2016 EPI N06 is available for licensing as of 07 Jan 2016. http://www.epipharm.ch/
- 01 Jan 2014 Phase-I/II clinical trials in Malignant melanoma (Prevention) in Switzerland (Topical) prior to January 2014